Sign in
GRI Stock Price, Chart, Stats & News
GRI Bio, Inc.
Save
168,884
Market cap
0.05x
Current P/E
–
Forward P/E
GRI chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -0.01% |
Operating margin | -41.48% |
Pretax margin | -41.41% |
Net margin | -41.41% |
Effective tax rate | – |
ROA | -137.96% |
ROE | -381.74% |
D/E | 0.01x |
Interest coverage ratio | – |
GRI valuation
P/E | 0.05x |
P/S | 0.01x |
P/B | 0.19x |
P/CF | -0.11x |
P/FCF | -0.02x |
P/OCF | -0.11x |
PEG | -0.00x |
EV multiple | -0.70x |
About
GRI Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutic agents within the United States. Its primary focus lies in addressing inflammatory, fibrotic, and autoimmune disorders. The company's leading drug candidate is GRI-0621, an oral inhibitor targeting type 1 Natural Killer T cells, which is currently undergoing Phase IIa clinical trials.
Similar securities
Based on sector and market capitalization
Report issue